cagrilintide/semaglutide 1 CagriSema 2.4 mg / 2.4 mg FDA NDA filing; Novo Nordisk data on file. 2 Garvey WT, Blüher M, Osorto Contreras CK, et al. Coadministered cagrilintide and semaglutide in adults with REDEFINE 1 Trial Finds Cagrilintide–Semaglutide

Common Symptoms May Include: Persistent fatigue or weakness Brain fog or difficulty concentrating Rapid heartbeat Shortness of breath with exertion Mood changes Numbness or tingling (advanced cases) Individuals at Higher Risk: Vegetarians and vegans Patients with celiac disease or other malabsorption disorders Those taking acid-reducing medications (PPIs, H2 blockers) Long-term oral contraceptive users Individuals with heavy alcohol use Patients with pernicious anemia Individuals with chronic gastrointestinal conditions Deficiency can negatively impact metabolism, neurologic function, and immune health if left unaddressed

GNCs Liquid L-Carnitine demonstrates an extremely useful ability of generating energy from the stored fats in body

Serial analyses of the metabolic profile showed consistently high HbA1c levels and body weight loss among GLP-1 RAs users

Pre-infusion CAR T cells of long-term responders (LTR) have increased oxidative phosphorylation, fatty acid oxidation, and pentose phosphate pathway activities, higher mitochondrial mass, tighter cristae, and lower mTOR expression compared to products of short-term responders